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counted at 6%/yr, were obtained from HRG codes E18–19. Ben-
eﬁts were discounted at 1.5%. Extensive multivariate sensitivity
analyses were done. RESULTS: In these patients with mean age
of 64yrs, 91% in class III, 23% dead at two yrs, CRT reduced
hospitalization for heart failure by 42%, leading to total costs
of £3500 per patient vs. £3000 with OPT. Based on 100 repli-
cations, mean improvement of 0.16 QALY (SD 0.009) is
achieved with CRT at mean net cost of £526 (SD £167) per
patient, a mean cost-effectiveness ratio of £3379/QALY. Exten-
sive sensitivity analyses revealed the greatest cost/QALY vari-
ability when the length of stay for heart failure was varied ± 25%
(£562–£6354). CONCLUSION: Despite the cost of implanta-
tion, cardiac resynchronization therapy decreases hospitaliza-
tions and increases QOL sufﬁciently to be cost-effective in
treating advanced heart failure.
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OBJECTIVE: Combination therapy with isosorbide dinitrate
and hydralazine was recently shown to signiﬁcantly improve
clinical and survival outcomes in African Americans with con-
gestive heart failure (CHF). The objective of this analysis was to
measure the potential economic impact of this combination in
the US African American population with CHF. METHODS:
The population of African Americans with heart failure was esti-
mated from US Census Bureau and US NCHS 2002 NHANES
data. We then aggregated and compared drug and hospital costs
over a 10-month period (the duration of the trial) under a com-
bination therapy scenario vs. a usual-care scenario. Costs were
calculated in 2004 USD from the payer perspective. Cost of the
generic combination drug regimen (40mg isosorbide dinitrate
and 75mg hydralazine, three times daily) was calculated using
the AWP. The rates of ﬁrst hospitalizations for treated and
untreated patients were drawn from the trial (24.4% of patients
without drug combination and 16.4% with drug combination).
Hospital costs were estimated based on Medicare reimbursement
rates for DRG 127. RESULTS: The use of the drug combination
resulted in a cost savings of over $270 million dollars for the
entire population (n = 800,097), or $338 per person receiving
the drug combination. Cost savings with the drug combination
were realized over a wide range of clinical and cost parameters
and assumptions. CONCLUSION: Usage of the isosorbide dini-
trate and hydralazine combination in African Americans with
heart failure can be expected to generate cost savings in addition
to the signiﬁcant clinical beneﬁts of the drug combination.
Further studies of the drug combination over longer time hori-
zons, brand pricing (including pricing for a yet-to-be-approved
combination pill), and consideration of other costs such as treat-
ment of adverse events and physician fees will give a more 
complete picture of the beneﬁts of the drug combination in this
population.
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OBJECTIVE: To evaluate the incremental differences of concur-
rent and persistent use of angiotensin-converting enzyme (ACE)
inhibitors, beta-blockers, loop diuretics, and digoxin on the risk
of hospitalization and total costs with heart failure patients
enrolled in a managed care organization. METHODS: Retro-
spective database analysis of outpatients diagnosed with heart
failure within a managed care organization covering 350,000
lives from January 1, 1997 to December 31, 1999. Linear and
logistic regression models were used to examine the association
between treatment regimens and all-cause hospitalizations or
total direct medical costs after controlling for patient demo-
graphics, comorbidities, and other risk factors. RESULTS: Of the
1903 patients meeting inclusion and exclusion criteria, 33.2% 
(n = 615) were observed not to have received any ACE inhibitor,
beta-blocker, loop diuretic, digoxin, or angiotensin-receptor
blockers (ARB). Subsequent multivariate analyses indicated that
the associated risk of one year, all-cause hospitalization was 2.5
times higher (p < 0.01) for patients taking none of these med-
ications relative to the overall sample, followed by a 43.6%
higher total health care costs (p < 0.01). Patients receiving three
or more of the speciﬁc medications analyzed were associated
with signiﬁcant decreases in risk of one year all-cause hospital-
ization of approximately 80% (p < 0.01) and decreases in total
costs of approximately 70% (p < 0.01) relative to those utiliz-
ing no therapy. CONCLUSION: This analysis appears to indi-
cate that a substantial portion of heart failure patients may be
receiving suboptimal pharmacotherapeutic care, resulting in a
higher associated risk of hospitalization and increase in total
health care costs. Conversely, patients that were adherent with
concurrent medication therapies were associated with decreases
in both hospitalizations and total costs. The implications of this
research suggest that quality improvement initiatives seek to
identify and manage those not being treated or adherent to estab-
lished evidence-based care.
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Caremark has developed an in-home program that monitors
weight and symptoms using a telemonitoring device. The device
includes a special scale and telephone. A registered nurse 
monitors for any changes in the participant and further assesses
their condition. The goal of this program is to encourage par-
ticipants to weigh daily to recognize early symptoms and to
follow their physician. OBJECTIVE: To evaluate the effective-
ness of the CarePatterns heart failure home monitoring program.
METHODS: Participants were selected based on severity, not on
dialysis, not in any other monitoring program, not going out of
town, and fewer than 320 pounds. The objectives were to get
participants to meet selected benchmarks after 60 days. These
included daily weight taking, action plan, and when to call their
physician, no changes in weight or symptoms in prior 28 days,
and fewer than three Non-Compliance alerts in 28 days.
RESULTS: In total, 100 participants enrolled, 51% male 49%
female, mean age of 73. Seventy-seven individuals started daily
weight taking. A total of 54, or 71%, of these participants met
the graduation requirement. The retention rate for the CarePat-
terns Heart Failure program was 98% for the enrolled group and
80% for the non-enrolled group p < 0.05, 45 participants had
an alert, resulting in 16 doctor visits, two emergency room visits
and two hospitalizations, 32 participants did not have an alert.
